EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in danish patients with non-small cell lung cancer

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 224-230

  Weber, Britta ^a   Hager, Henrik ^a   Sorensen, Boe S ^a   McCulloch, Tine ^c   Mellemgaard, Anders ^b   Khalil, Azza Ahmed ^a   Nexo, Ebba ^a   Meldgaard, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Epidermal growth factor receptor; Epidermal growth factor receptor mutations; Erlotinib; Non small cell lung cancer; Targeted treatment; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ISOLEUCINE; PLATINUM COMPLEX; SERINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC KIT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXON; FEMALE; GENE DELETION; GENE INSERTION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUTATION RATE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; POINT MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SMOKING; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; WILD TYPE;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS; ERLOTINIB; NON-SMALL CELL LUNG CANCER; TARGETED TREATMENT; TYROSINE KINASE INHIBITORS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DENMARK; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84892845647     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.023     Document Type: Article

References (31)

1. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(July (2)):123-132.
2. Capelletto E., Novello S. Emerging new agents for the management of patients with non-small cell lung cancer. Drugs 2012, 72(June (Suppl. 1)):37-52.
3. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future. J Clin Oncol 2013, 31(March (8)):1105-1111.
4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(May (21)):2129-2139.
5. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(June (5676)):1497-1500.
6. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101(September (36)):13306-13311.
7. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006, 24(July (21)):3340-3346.
8. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26(May (15)):2442-2449.
9. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(September (10)):958-967.
10. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(September (10)):947-957.
11. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(February (2)):121-128.
12. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(June (25)):2380-2388.
13. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(March (5)):339-346.
14. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(March (3)):239-246.
15. Yoshioka H., Hotta K., Kiura K., Takigawa N., Hayashi H., Harita S., et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 2010, 5(January (1)):99-104.
16. Kobayashi T., Koizumi T., Agatsuma T., Yasuo M., Tsushima K., Kubo K., et al. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2012, 69(May (5)):1241-1246.
17. Zugazagoitia J., Puente J., Gonzalez-Larriba J.L., Manzano A., Sotelo M., Hernandez S., et al. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice. Oncology 2013, 84(February (5)):255-264.
18. Travis W.D., Garg K., Franklin W.A., Wistuba I.I., Sabloff B., Noguchi M., et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 2006, 1(November (9 Suppl.)):S13-S19.
19. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(February (3)):205-216.
20. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013, April.
21. Lopez-Rios F., Angulo B., Gomez B., Mair D., Martinez R., Conde E., et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol 2013, 66(May (5)):381-385.
22. Ohba T., Toyokawa G., Kometani T., Nosaki K., Hirai F., Yamaguchi M., et al. The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surg Today 2013, April.
23. Liam C.K., Wahid M.I., Rajadurai P., Cheah Y.K., Ng T.S. Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients. J Thorac Oncol 2013, April.
24. Couraud S., Zalcman G., Milleron B., Morin F., Souquet P.J. Lung cancer in never smokers-a review. Eur J Cancer 2012, 48(June (9)):1299-1311.
25. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(March (3)):169-181.
26. Boch C., Kollmeier J., Roth A., Stephan-Falkenau S., Misch D., Gruning W., et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open 2013, 3(April (4)). [print 2013]. 10.1136/bmjopen-2013-002560.
27. Wu J.Y., Wu S.G., Yang C.H., Gow C.H., Chang Y.L., Yu C.J., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008, 14(August (15)):4877-4882.
28. Wu J.Y., Yu C.J., Chang Y.C., Yang C.H., Shih J.Y., Yang P.C. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011, 17(June (11)):3812-3821.
29. Yasuda H., Kobayashi S., Costa D.B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012, 13(January (1)):e23-e31.
30. Asahina H., Yamazaki K., Kinoshita I., Yokouchi H., Dosaka-Akita H., Nishimura M. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 2006, 54(December (3)):419-422.
31. Masago K., Fujita S., Irisa K., Kim Y.H., Ichikawa M., Mio T., et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC>ATC in exon 20 (S768I). Jpn J Clin Oncol 2010, 40(November (11)):1105-1109.